{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T04:13:42Z","timestamp":1775880822462,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Since the available data for bloodstream infections in solid malignancy tumors are somewhat limited in Palestine, prevention of infection before the occurrence, controlling it when it occurs, and implementing stewardship programs are important ways in the whole therapy of solid tumor patients, which is becoming challenging recently with the evolution of more antimicrobial drug-resistant pathogens. Therefore, our study aims to assess the microbial spectrum and antimicrobial sensitivity and the overall outcome related to many clinical risk factors in patients with solid tumor patients seeking care in a referral hospital as an experience from a developing country.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From the onset of 2018 to the end of 2020, a total of 116 episodes with positive blood cultures were retrospectively studied and analyzed in 96 patients who had solid tumors in a referral hospital in Palestine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 116 positive blood cultures in 96 patients with a male to female ratio of 1:1. The mean age was 58\u00a0years. Breast cancer was the tumor most frequently recorded (13.5%), followed by urinary tract tumors (10.4%). The most common source of episodes with positive blood culture was catheter-related. Gram-positive bacteria accounted for 52.6% of blood cultures with the predomination of Staphylococcus species. On the contrary, Gram-negative bacteria were documented in 39.7% of the cultures, with <jats:italic>E. coli<\/jats:italic>\u00a0being the most frequent bacteria. Regarding fungi that were only <jats:italic>Candida species<\/jats:italic>, it was isolated in 15.5% of the cultures.28.4% of patients started on a single antimicrobial as an initial regimen, the remaining started combination antimicrobial therapy. The initial antimicrobials used most frequently were aminoglycosides in 29.3% of the episodes. All species of <jats:italic>Staphylococcus<\/jats:italic> were sensitive to vancomycin. <jats:italic>Enterococcus species<\/jats:italic> were fully resistant to ciprofloxacin. In the case of <jats:italic>E. coli,<\/jats:italic> the isolates were 100% sensitive to imipenem, meropenem, and amikacin and were mostly resistant to ampicillin, where the sensitivity was only about 19.5%. <jats:italic>P.aeruginosa<\/jats:italic> was sensitive in 83.3% of cultures to both piperacillin-tazobactam and gentamicin, but highly resistant to imipenem, in which sensitivity decreased to 50%. The isolates of <jats:italic>Klebsiella species<\/jats:italic> were 72.2% sensitive to gentamicin, meropenem, and imipenem and 100% resistant to ampicillin. <jats:italic>A. baumannii<\/jats:italic> was 50% sensitive to trimethoprim-sulfamethoxazole. Candida species showed high sensitivity to both caspofungin and flucytosine (83.3%), followed by 77.8% sensitivity to voriconazole. Death was reported in 27.6% of the episodes and there was a significant relationship between shock at presentation and death (<jats:italic>p<\/jats:italic>\u2009=\u20090.010).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The findings of this investigation confirm the prevalent BSI seen in patients with solid malignancies and demonstrate a significant percentage of antibiotic resistance. Therefore, stewardship programs that dig deep before using any type of antimicrobials will help reduce the risk of resistance to antibiotics. In addition, the implementation of infection control surveillance plays an important role in decreasing the risk of contamination.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07375-6","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T06:02:42Z","timestamp":1650261762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Microbial spectrum and drug resistance profile in solid malignancies in a large tertiary hospital from Palestine"],"prefix":"10.1186","volume":"22","author":[{"given":"Rama","family":"Rabayah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranyah B.","family":"Alsayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adham Abu","family":"Taha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husam","family":"Salameh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riad","family":"Amer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Sabateen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banan M.","family":"Aiesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa\u2019ed H.","family":"Zyoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"issue":"3","key":"7375_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/MD.0000000000000026","volume":"93","author":"M Mar\u00edn","year":"2014","unstructured":"Mar\u00edn M, Gudiol C, Garcia-Vidal C, Ardanuy C, Carratal\u00e0 J. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine (Baltimore). 2014;93(3):143\u20139.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"7375_CR2","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.31557\/APJCP.2019.20.5.1471","volume":"20","author":"HA Vahedian-Ardakani","year":"2019","unstructured":"Vahedian-Ardakani HA, Moghimi M, Shayestehpour M, Doosti M, Amid N. Bacterial Spectrum and Antimicrobial Resistance Pattern in Cancer Patients with Febrile Neutropenia. Asian Pac J Cancer Prev. 2019;20(5):1471\u20134.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"11","key":"7375_CR3","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1111\/imj.13609","volume":"47","author":"N Slavova-Azmanova","year":"2017","unstructured":"Slavova-Azmanova N, Haddow L, Hohnen H, Coombs G, Robinson JO, Ives A. Admissions for antibiotic-resistant infections in cancer patients during first year of cancer diagnosis: a cross-sectional study. Intern Med J. 2017;47(11):1306\u201310.","journal-title":"Intern Med J"},{"issue":"3","key":"7375_CR4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/21505594.2016.1141161","volume":"7","author":"C Gudiol","year":"2016","unstructured":"Gudiol C, Aguado JM, Carratal\u00e0 J. Bloodstream infections in patients with solid tumors. Virulence. 2016;7(3):298\u2013308.","journal-title":"Virulence"},{"issue":"2","key":"7375_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3390\/ijms22020859","volume":"22","author":"AA Khan","year":"2021","unstructured":"Khan AA, Manzoor KN, Sultan A, Saeed M, Rafique M, Noushad S, Talib A, Rentschler S, Deigner HP. Pulling the Brakes on Fast and Furious Multiple Drug-Resistant (MDR) Bacteria. Int J Mol Sci. 2021;22(2):859.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7375_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/antibiotics10010007","volume":"10","author":"G Ziolkowski","year":"2020","unstructured":"Ziolkowski G, Pawlowska I, Stasiowski M, Jachowicz E, Wojkowska-Mach J, Bielecki T. Multidrug-resistant micro-organisms associated with urinary tract infections in orthopedic patients: a retrospective laboratory-based study. Antibiotics (Basel). 2020;10(1):7.","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"7375_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13756-019-0471-0","volume":"8","author":"D Nathwani","year":"2019","unstructured":"Nathwani D, Varghese D, Stephens J, Ansari W, Martin S, Charbonneau C. Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review. Antimicrob Resist Infect Control. 2019;8(1):35.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"4","key":"7375_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/bcp.13486","volume":"84","author":"MR Khdour","year":"2018","unstructured":"Khdour MR, Hallak HO, Aldeyab MA, Nasif MA, Khalili AM, Dallashi AA, Khofash MB, Scott MG. Impact of antimicrobial stewardship programme on hospitalized patients at the intensive care unit: a prospective audit and feedback study. Br J Clin Pharmacol. 2018;84(4):708\u201315.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"7375_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s15010-004-3049-5","volume":"32","author":"M Anatoliotaki","year":"2004","unstructured":"Anatoliotaki M, Valatas V, Mantadakis E, Apostolakou H, Mavroudis D, Georgoulias V, Rolston KV, Kontoyiannis DP, Galanakis E, Samonis G. Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome. Infection. 2004;32(2):65\u201371.","journal-title":"Infection"},{"issue":"4","key":"7375_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/00005792-198607000-00002","volume":"65","author":"LS Elting","year":"1986","unstructured":"Elting LS, Bodey GP, Fainstein V. Polymicrobial septicemia in the cancer patient. Medicine (Baltimore). 1986;65(4):218\u201325.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"7375_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/0002-9343(77)90876-2","volume":"62","author":"C Singer","year":"1977","unstructured":"Singer C, Kaplan MH, Armstrong D. Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases. Am J Med. 1977;62(5):731\u201342.","journal-title":"Am J Med"},{"issue":"Suppl 2","key":"7375_CR12","doi-asserted-by":"publisher","first-page":"S322","DOI":"10.1093\/clinids\/17.Supplement_2.S322","volume":"17","author":"BS Koll","year":"1993","unstructured":"Koll BS, Brown AE. The changing epidemiology of infections at cancer hospitals. Clin Infect Dis. 1993;17(Suppl 2):S322-328.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"7375_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/BF01695660","volume":"15","author":"E Gonz\u00e1lez-Barca","year":"1996","unstructured":"Gonz\u00e1lez-Barca E, Fern\u00e1ndez-Sevilla A, Carratal\u00e1 J, Gra\u00f1ena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis. 1996;15(4):291\u20136.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"7375_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1128\/AAC.39.2.445","volume":"39","author":"A Cometta","year":"1995","unstructured":"Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 1995;39(2):445\u201352.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"7375_CR15","first-page":"1","volume":"4","author":"J Calvo-Lon","year":"2018","unstructured":"Calvo-Lon J, Landaverde DU, Ramos-Esquivel A, Villalobos-Vindas JM. Epidemiology and outcomes of bloodstream infections in patients with solid tumors in a central american population at Mexico Hospital, San Jose, Costa Rica. J Glob Oncol. 2018;4(4):1\u20136.","journal-title":"J Glob Oncol"},{"issue":"3","key":"7375_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/imj.13646","volume":"48","author":"N De Silva","year":"2018","unstructured":"De Silva N, Jackson J, Steer C. Infections, resistance patterns and antibiotic use in patients at a regional cancer centre. Intern Med J. 2018;48(3):323\u20139.","journal-title":"Intern Med J"},{"issue":"1","key":"7375_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12941-019-0339-4","volume":"18","author":"MM Zafer","year":"2019","unstructured":"Zafer MM, El-Mahallawy HA, Abdulhak A, Amin MA, Al-Agamy MH, Radwan HH. Emergence of colistin resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli strains isolated from cancer patients. Ann Clin Microbiol Antimicrob. 2019;18(1):40.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"16","key":"7375_CR18","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038\u201351.","journal-title":"J Clin Oncol"},{"issue":"8","key":"7375_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10096-007-0320-6","volume":"26","author":"I Raad","year":"2007","unstructured":"Raad I, Hachem R, Hanna H, Bahna P, Chatzinikolaou I, Fang X, Jiang Y, Chemaly RF, Rolston K. Sources and outcome of bloodstream infections in cancer patients: the role of central venous catheters. Eur J Clin Microbiol Infect Dis. 2007;26(8):549\u201356.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"7375_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/jac\/21.suppl_C.157","volume":"21","author":"A Del Favero","year":"1988","unstructured":"Del Favero A, Menichetti F, Bucaneve G, Minotti V, Pauluzzi S. Septicaemia due to gram-positive cocci in cancer patients. J Antimicrob Chemother. 1988;21:157\u201365.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"7375_CR21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/infdis\/165.3.591","volume":"165","author":"J Cohen","year":"1992","unstructured":"Cohen J. Empiric use of vancomycin in the febrile neutropenic patient. J Infect Dis. 1992;165(3):591.","journal-title":"J Infect Dis"},{"issue":"5","key":"7375_CR22","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/clinids\/20.5.1126","volume":"20","author":"MB Edmond","year":"1995","unstructured":"Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, Wenzel RP. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis. 1995;20(5):1126\u201333.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"7375_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/QCO.0000000000000038","volume":"27","author":"EM Trecarichi","year":"2014","unstructured":"Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis. 2014;27(2):200\u201310.","journal-title":"Curr Opin Infect Dis"},{"issue":"Suppl 7","key":"7375_CR24","doi-asserted-by":"publisher","first-page":"S521","DOI":"10.1093\/cid\/ciz824","volume":"69","author":"P Nordmann","year":"2019","unstructured":"Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria. Clin Infect Dis. 2019;69(Suppl 7):S521-s528.","journal-title":"Clin Infect Dis"},{"key":"7375_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1479-5876-7-14","volume":"7","author":"HM Ashour","year":"2009","unstructured":"Ashour HM, El-Sharif A. Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients. J Transl Med. 2009;7:14.","journal-title":"J Transl Med"},{"issue":"9","key":"7375_CR26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.15537\/smj.2016.9.14211","volume":"37","author":"FE Al-Otaibi","year":"2016","unstructured":"Al-Otaibi FE, Bukhari EE, Badr M, Alrabiaa AA. Prevalence and risk factors of Gram-negative bacilli causing blood stream infection in patients with malignancy. Saudi Med J. 2016;37(9):979\u201384.","journal-title":"Saudi Med J"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07375-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07375-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07375-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T07:17:02Z","timestamp":1650352622000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07375-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7375"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07375-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,18]]},"assertion":[{"value":"26 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All aspects of the study protocol, including access to and use of patient clinical information, had been approved by the <i>Institutional Review Boards (IRB) of An-Najah National University.<\/i> We confirm that the collected data were used only for clinical research. The information was confidential and not used for any purpose other than that in this study. The data collected was only with limited access to the working staff in the project. Identifiable patient information and hospital name were not shared; we used numbers as codes for patients instead of their names. All the methods used in the study were carried out in accordance with the relevant guidelines and regulations. The IRB of An-Najah National University waived the need for informed consent since we used retrospective data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"385"}}